TrialLancet (London, England)2018

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Masatoshi Kudo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.